Open access · CC-BY
via OpenAlex
p16 a biomarker of aging and tolerance for cancer therapy
Hyman B. Muss, Andrew B. Smitherman, William A. Wood, Kirsten A. Nyrop, Sascha A. Tuchman, Paramjeet K. Randhawa, Amy Entwistle, Natalia Mitin, Shlomit Strulov Shachar
Translational Cancer Research · 2020 · ▲ 77 citations
Abstract
There is great variability in life-expectancy, physical, cognitive, and functional domains in cancer patients of similar chronologic age. Nowhere is this more apparent than among middle-aged and older patients. However, even in younger patients of similar age, extensive exposure to environmental stressors can cause great variability in health status. A biomarker that would reflect biologic age and any and all health deficits in a cancer patient at a distinct point in time might help predict long term outcomes related to treatment, especially toxicity and overall survival. p16 INK4a (hereafter referred to as p16) expression represents an ideal biomarker that reflects both cellular senescence(definition) and biologic aging. In murine models, p16 expression reflects biologic aging in almost all organs. Preliminary findings in patients with cancer support p16 measurement as a marker of physiologic aging and predictor of toxicity in patients treated with chemotherapy. This review describes the role of p16 in cell senescence, the methodology of p16 measurement in humans, preliminary studies of p16 in humans, and the potential clinical utility of p16 in guiding treatment for cancer patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.21037/tcr.2020.03.39
- Canonical
- link ↗
- Fetched
- 2026-06-22 MST
Cite this
APA
Muss, H.B., Smitherman, A.B., Wood, W.A., Nyrop, K.A., Tuchman, S.A., Randhawa, P.K., Entwistle, A., Mitin, N., & Shachar, S.S. (2020). p16 a biomarker of aging and tolerance for cancer therapy. <em>Translational Cancer Research</em>. https://doi.org/10.21037/tcr.2020.03.39
Vancouver
Muss HB, Smitherman AB, Wood WA, Nyrop KA, Tuchman SA, Randhawa PK, et al. p16 a biomarker of aging and tolerance for cancer therapy. Translational Cancer Research. 2020. doi:10.21037/tcr.2020.03.39.
BibTeX
@article{hyman2020pabiom,
title = {p16 a biomarker of aging and tolerance for cancer therapy},
author = {Hyman B. Muss and Andrew B. Smitherman and William A. Wood and Kirsten A. Nyrop and Sascha A. Tuchman and Paramjeet K. Randhawa and Amy Entwistle and Natalia Mitin and Shlomit Strulov Shachar},
journal = {Translational Cancer Research},
year = {2020},
doi = {10.21037/tcr.2020.03.39},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
medRxiv 2026
Preprint · CC-BY
Comparing epigenetic puberty and epigenetic clocks as biomarkers of adult biological aging and health
2026
Preprint · OA
Comparing epigenetic puberty and epigenetic clocks as biomarkers of adult biological aging and health
Scientific Reports 2025
Open access · CC-BY
Epigenetic aging acceleration among World Trade Center-exposed community members
Geriatrics and gerontology international/Geriatrics & gerontology international 2020
Open access · OA
Chapter 1 Frailty: Definition, diagnosis, epidemiology
Clinical Epigenetics 2021
Open access · CC-BY
Epigenetic age is associated with baseline and 3-year change in frailty in the Canadian Longitudinal Study on Aging
medRxiv 2023
Preprint · CC-BY